Sickle cell gene therapies offer new hope, but access remains a major challenge
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Following the 2023 FDA approval of Casgevy and Lyfgenia, gene therapies offer new hope for severe sickle cell disease, which can shorten life expectancy by 20 years. However, high costs, complex procedures, and limited specialized centers hinder access for thousands of patients, notes Dr. Edward Donnell Ivy of the Sickle Cell Disease Association of America.
Continue in the app — vote & join in ➔Source: CNBC Top News · via ahirlevel.hu